(Date:7/25/2008)... Authority offers patients consumers tips and enco...nt safety, HARRISBURG, Pa., July 25 /PRNewswire-U...ority today supports "National Patient Safety Day"...and their families to,participate fully in their h...ing they can about their surgery or illness., "We...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)...ck to benefit ALS Therapy Alliance to be presented...ight, WOONSOCKET, R.I., July 25 /PRNewswire/ -- C...raised a record-breaking $4.4 million in just 21 d...gn for ALS research. This is,the seventh year of t...aised more than $15 million for ALS research. This...
(Date:7/25/2008)... The Retina Group of New York wi...lated macular degeneration especially designed for...ale Public Library at 116 Merritts Road, Farmingda...15. Attendance is free and refreshments will be pr...516) 939-6100. , Hicksvil...
Breaking Medicine News(10 mins):Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3(Date:7/23/2008)... Study results pending publication in July print e... available on Web, INDIANAPOLIS, July 23 /PRNewsw...evaluating the use of N-terminal pro-B-type natriu...alue of NT-proBNP for risk,stratification in predi...V-AE) in patients treated with non-steroidal anti-...
(Date:7/23/2008)... BOSTON, July 23 /- FluoroPharma Inc....ing agents for the Positron Emission Tomography,(P... BFPET, its novel,Fluorine-18 labeled tracer for m...,s second cardiovascular product to complete Phase...agent, designed to assess the blood flow in the,he...
(Date:7/23/2008)... SEATTLE, July 23 /- Dendre...at it expects the Independent Data,Monitoring Comm... analysis,of overall survival relating to the Comp...denoCarcinoma Treatment, also known as D9902B) cli...E is the Company,s investigational,active cellular...
(Date:7/22/2008)... - Strong efficacy results from a multi-center 293....com , Toronto Stock Exchange Symbol: CYT, MONTR...Technologies,Inc., the global leader in cryotherap...ounced that results previously presented from thre...product, Arctic Front(R),were published earlier t...
Breaking Medicine Technology:Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3New AARP Report Finds Mixed Results Among State Governments Efforts to Balance Long Term Care Services Under Medicaid 23826 1New AARP Report Finds Mixed Results Among State Governments Efforts to Balance Long Term Care Services Under Medicaid 23826 2New AARP Report Finds Mixed Results Among State Governments Efforts to Balance Long Term Care Services Under Medicaid 23826 3RAC Companies Respond to CMS Report on RAC Demonstration Program 23824 1RAC Companies Respond to CMS Report on RAC Demonstration Program 23824 2Using Mediasite for Lecture Capture Found to Enhance Student Performance at Penn State Milton S Hershey Medical Center 23823 1Using Mediasite for Lecture Capture Found to Enhance Student Performance at Penn State Milton S Hershey Medical Center 23823 2Using Mediasite for Lecture Capture Found to Enhance Student Performance at Penn State Milton S Hershey Medical Center 23823 3Using Mediasite for Lecture Capture Found to Enhance Student Performance at Penn State Milton S Hershey Medical Center 23823 4Using Mediasite for Lecture Capture Found to Enhance Student Performance at Penn State Milton S Hershey Medical Center 23823 5NuVal 28TM 29 Nutritional Scoring System Will Debut in Major U S Chains This September 23821 1NuVal 28TM 29 Nutritional Scoring System Will Debut in Major U S Chains This September 23821 2NuVal 28TM 29 Nutritional Scoring System Will Debut in Major U S Chains This September 23821 3... CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2007 -...used biopharmaceutical,company, announced today th... granted Fast Track designation for its novel hist...otherapy of,previously treated peripheral T-cell l...ed that it has reached an agreement with the,FDA u...
... MADISON, N.J., May 9 /PRNewswire-FirstCall/ -- W...d and Drug Administration,s (FDA),San Juan Distric...FDA re-inspection of its Guayama, Puerto Rico manu...classification of the site.,The new classification...r been corrected by the Company or do not merit an...
Other Medicine Technology:Gloucester Pharmaceuticals Receives Fast Track Designation for,Romidepsin in Peripheral T-Cell Lymphoma 2Gloucester Pharmaceuticals Receives Fast Track Designation for,Romidepsin in Peripheral T-Cell Lymphoma 3FDA Re-Inspection Results in Positive Re-Classification of Guayama,Facility 2FDA Re-Inspection Results in Positive Re-Classification of Guayama,Facility 3The GENIE is the proven electrophoretic transfer apparatus incorporating state-of-the-art plate electrodes for the ultimate in field uniformity. Its design allows for a very close positioning of the
The HEP-3, with a transfer area of 35cmW x 45cmL, is designed specifically for the transfer of nucleic acids from sequencing gels to nylon membranes.
The Trans-Blot SD semi-dry transfer cell allows fast, efficient and economical blotting. Using a platinum-coated titanium plate as the anode and a stainless steel plate as the cathode, the Trans-Blot
...A and RNA from agarose gels to hybridization membr...nd efficiency of transfer by allowing high pressur...em allowing electrophoresis, gel treatment, transf...rs required for conventional methods ,Positive pre...
Medicine Products: